1. In Vivo
  2. >>Innovation

2020 Vision For Biopharma

Welcome To The New Roaring Twenties

 
• By Lucie Ellis-Taitt

Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.

Sphere
Peering Into The Crystal Ball As A New Decade Approaches • Source: Shutterstock

Looking back a century, in 1920, French researchers perfected a tuberculosis vaccine for use in children from infected households. And the first tetanus anatoxin was produced. In the same year, Frederick Banting of the University of Toronto began a development journey that would eventually lead to the successful use of purified insulin in diabetics. Banting, along with John Macleod, was in 1923 awarded the Nobel Prize in Medicine for the discovery of insulin.

One hundred years later, it is a very different world for medicine discovery and development, and for patients in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy